Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2022 May 7

PMID 35524749

Authors

David A Baidal

Megan Warnock

Ping Xu

Susan Geyer

Jennifer B Marks

Antoinette Moran

Jay Sosenko

Carmella Evans-Molina

Affiliations

Soon will be listed here.

Abstract

Context: Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D).

Objective: Assess whether oral glucose tolerance test (OGTT) measures could serve as FPIR alternatives in their ability to predict T1D in autoantibody positive (Aab+) subjects.

Design: OGTT and IVGTT were performed within 30 days of each other. Eleven OGTT variables were evaluated for (1) correlation with FPIR and (2) T1D prediction.

Setting: Type 1 Diabetes TrialNet "Oral Insulin for Prevention of Diabetes in Relatives at Risk for T1D" (TN-07) and Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) studies clinical sites.

Patients: TN-07 (n = 292; age 9.4 ± 6.1 years) and DPT-1 (n = 194; age 15.1 ± 10.0 years) Aab + relatives of T1D individuals.

Main Outcome Measures: (1) Correlation coefficients of OGTT measures with FPIR and (2) T1D prediction at 2 years using area under receiver operating characteristic (ROCAUC) curves.

Results: Index60 showed the strongest correlation in DPT-1 (r = -0.562) but was weaker in TN-07 (r = -0.378). C-peptide index consistently showed good correlation with FPIR across studies (TN-07, r = 0.583; DPT-1, r = 0.544; P < 0.0001). Index60 and C-peptide index had the highest ROCAUCs for T1D prediction (0.778 vs 0.717 in TN-07 and 0.763 vs 0.721 in DPT-1, respectively; P = NS), followed by FPIR (0.707 in TN-07; 0.628 in DPT-1).

Conclusions: C-peptide index was the strongest measure to correlate with FPIR in both studies. Index60 and C-peptide index had the highest predictive accuracy for T1D and were comparable. OGTTs could be considered instead of IVGTTs for subject stratification in T1D prevention trials.

Citing Articles

Quantifying beta cell function in the preclinical stages of type 1 diabetes.

Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C Diabetologia. 2023; 66(12):2189-2199.

PMID: 37712956 PMC: 10627950. DOI: 10.1007/s00125-023-06011-5.

Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us.

Galderisi A Pediatr Endocrinol Diabetes Metab. 2023; 29(1):1-3.

PMID: 37218722 PMC: 10226454. DOI: 10.5114/pedm.2023.126360.

Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice.

Mao R, Wang J, Xu Y, Wang Y, Wu M, Mao L Drug Deliv. 2023; 30(1):2173339.

PMID: 36719009 PMC: 9891168. DOI: 10.1080/10717544.2023.2173339.

β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT.

Galderisi A, Evans-Molina C, Martino M, Caprio S, Cobelli C, Moran A J Clin Endocrinol Metab. 2022; 108(6):1376-1386.

PMID: 36546354 PMC: 10188312. DOI: 10.1210/clinem/dgac740.

References

Utzschneider K, Prigeon R, Faulenbach M, Tong J, Carr D, Boyko E . Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2008; 32(2):335-41. PMC: 2628704. DOI: 10.2337/dc08-1478. View

Tfayli H, Bacha F, Gungor N, Arslanian S . Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two?. Diabetes Care. 2009; 33(3):632-8. PMC: 2827522. DOI: 10.2337/dc09-0305. View

Mari A, Tura A, Pacini G, Kautzky-Willer A, Ferrannini E . Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. Diabet Med. 2008; 25(6):671-7. DOI: 10.1111/j.1464-5491.2008.02441.x. View

Goran M, Gower B . Longitudinal study on pubertal insulin resistance. Diabetes. 2001; 50(11):2444-50. DOI: 10.2337/diabetes.50.11.2444. View

Srikanta S, Ganda O, Rabizadeh A, Soeldner J, Eisenbarth G . First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med. 1985; 313(8):461-4. DOI: 10.1056/NEJM198508223130801. View

Vardi P, Crisa L, Jackson R . Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia. 1991; 34(2):93-102. DOI: 10.1007/BF00500379. View

. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002; 346(22):1685-91. DOI: 10.1056/NEJMoa012350. View

Krischer J, Schatz D, Bundy B, Skyler J, Greenbaum C . Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2017; 318(19):1891-1902. PMC: 5798455. DOI: 10.1001/jama.2017.17070. View

Chase H, Voss M, Hoops S, OBrien D, Dobersen M . Diagnosis of pre-type I diabetes. J Pediatr. 1987; 111(6 Pt 1):807-12. DOI: 10.1016/s0022-3476(87)80192-0. View

10.

Sosenko J, Mahon J, Rafkin L, Lachin J, Krause-Steinrauf H, Krischer J . A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatr Diabetes. 2010; 12(2):85-90. PMC: 2955175. DOI: 10.1111/j.1399-5448.2010.00662.x. View

11.

Bingley P, Colman P, Eisenbarth G, Jackson R, McCulloch D, Riley W . Standardization of IVGTT to predict IDDM. Diabetes Care. 1992; 15(10):1313-6. DOI: 10.2337/diacare.15.10.1313. View

12.

Williams A, Long A . Following the fate of the failing β-cell: new insights from first-phase insulin responses. Diabetes. 2013; 62(12):3990-2. PMC: 3837054. DOI: 10.2337/db13-1314. View

13.

Sosenko J, Skyler J, Beam C, Krischer J, Greenbaum C, Mahon J . Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes. 2013; 62(12):4179-83. PMC: 3837047. DOI: 10.2337/db13-0656. View

14.

Chase H, Garg S, Klingensmith G, Norris L, Ruskey C, OBrien D . Prediction of the course of pre-type I diabetes. J Pediatr. 1991; 118(6):838-41. DOI: 10.1016/s0022-3476(05)82192-4. View

15.

Ball G, Huang T, Gower B, Cruz M, Shaibi G, Weigensberg M . Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty. J Pediatr. 2006; 148(1):16-22. DOI: 10.1016/j.jpeds.2005.08.059. View

16.

Evans-Molina C, Sims E, DiMeglio L, Ismail H, Steck A, Palmer J . β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight. 2018; 3(15). PMC: 6129118. DOI: 10.1172/jci.insight.120877. View

17.

Henderson M, Baillargeon J, Rabasa-Lhoret R, Chiasson J, Hanley J, Lambert M . Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test. Diabetes Metab. 2012; 38(4):309-15. DOI: 10.1016/j.diabet.2012.02.002. View

18.

Bacha F, Gungor N, Arslanian S . Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008; 152(5):618-21. PMC: 2396878. DOI: 10.1016/j.jpeds.2007.11.044. View

19.

Xu P, Beam C, Cuthbertson D, Sosenko J, Skyler J, Krischer J . Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care. 2012; 35(10):1975-80. PMC: 3447832. DOI: 10.2337/dc12-0183. View

20.

Bergman R . Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989; 38(12):1512-27. DOI: 10.2337/diab.38.12.1512. View